Annahita Keravala News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Annahita keravala. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Annahita Keravala Today - Breaking & Trending Today

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

/PRNewswire/ Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal. ....

Bruxelles Capitale , United States , Thomas Chalberg , Annahita Keravala , Genascence Corporation , European American Society Of Gene , European American Society , Cell Therapy , Annual Congress , Defense Peer Reviewed Medical Research Program , Health Care Amp Hospitals , Pharmaceuticals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries , Trade Show News ,

Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis

Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Palo Alto , Mariat Millan , Genascence Corporationgenascence , Philip Conaghan , Thomas Chalberg , Christopherh Evans , Annahita Keravala , Musculoskeletal Gene Therapy Research Laboratory , Langone Health , California Institute For Regenerative Medicine , National Institutes Of Health , University Of Florida , Building Interdisciplinary Research Careers In Women Health , Prnewswire Genascence Corporation , University Of Leeds , California Institute , Regenerative Medicine , Placebo Controlled Dose Ranging Study Evaluating , Knee Osteoarthritis , Chief Scientific Officer , Posy Krehbiel Professor , Mayo Clinic , Musculoskeletal Medicine , Distinguished Professor , Aging Research ,

Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis

/PRNewswire/ Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal. ....

United States , Mariat Millan , Philip Conaghan , Thomas Chalberg , Christopherh Evans , Annahita Keravala , Musculoskeletal Gene Therapy Research Laboratory , Building Interdisciplinary Research Careers In Women Health , California Institute For Regenerative Medicine , Prnewswire Genascence Corporation , National Institutes Of Health , University Of Leeds , California Institute , Regenerative Medicine , Placebo Controlled Dose Ranging Study Evaluating , Knee Osteoarthritis , Chief Scientific Officer , Posy Krehbiel Professor , Mayo Clinic , Musculoskeletal Medicine , Distinguished Professor , Aging Research , Building Interdisciplinary Research Careers , Davis School ,

Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board

Proceeds will be used to advance clinical program of GNSC-001, company s lead candidate in osteoarthritis (OA) Brian Kotzin, M.D., and Jackson Streeter, M.D.,. ....

United States , National Institutes Of Health , Palo Alto , Stanford University , University Of Maryland School Medicine , Brian Kotzin , Paul Robbins , Byers Kraus , Philip Conaghan , Marcc Hochberg , Pacira Biosciences , Steven Ghivizzani , Mukundan Attur , Thomasj Schnitzer , Ron Ellis , John Fraser Wright , Thomas Chalberg , Christopherh Evans , Annahita Keravala , American Society For Gene Cell Therapy , Duke University School Of Medicine , Musculoskeletal Gene Therapy Research Laboratory , Pacira Biosciences Inc , Oncorus Inc , University Of Florida Ventures , American Society Of Gene Cell Therapy ,

Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis

Share this article
PALO ALTO, Calif., May 5, 2021 /PRNewswire/
Genascence Corporation, a clinical-stage biotechnology company developing life-changing gene therapy products for prevalent musculoskeletal diseases, today announced that dosing across all three cohorts has been completed in the Phase 1 clinical trial of GNSC-001 for the treatment of osteoarthritis (OA).
GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation as well as cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint. ....

United States , Palo Alto , Stanford University , Paul Robbins , Philip Conaghan , Steven Ghivizzani , Mukundan Attur , John Fraser Wright , Christopher Evans , Thomas Chalberg , Christopherh Evans , Annahita Keravala , Langone Health , Scientific Co , Rocket Pharmaceuticals , University Of Florida , Grossman School Of Medicine , American Society Of Gene , University Of Minnesota , University Of Leeds , Genascence Corporation , University Of Florida College Medicine , American Society , Cell Therapy , Annual Meeting , Osteoarthritis Gene Therapy ,